ALKERMES | ALKS - 销售收入

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.45B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	销售	更改		日
AbbVie	USD 16.99B		1.99B	2026-06
Acadia Pharmaceuticals	USD 307.96M		39.9M	2026-06
ALKERMES	USD 496.01M		103.1M	2026-06
Amgen	USD 10.1B		1.48B	2026-06
Biogen	USD 2.74B		490M	2026-06
BioMarin Pharmaceutical	USD 990M		224M	2026-06
Bristol-Myers Squibb	USD 12.97B		1.48B	2026-06
Coherus Biosciences	USD 12.75M		1.18M	2025-12
Eli Lilly	USD 22.97B		3.17B	2026-06
Gilead Sciences	USD 7.8B		800M	2026-06
Heron Therapeutics	USD 40.59M		2.38M	2025-12
Ionis Pharmaceuticals	USD 268M		22M	2026-06
J&J	USD 25.31B		1.21B	2026-06
Merck	USD 16.6B		310M	2026-06
Minerva Neurosciences	USD 0		0	2024-09
Nektar Therapeutics	USD 10.86M		10.95M	2026-03
Neurocrine Biosciences	USD 959M		148M	2026-06
Otsuka Holdings	JPY 702.05B		71.71B	2026-06
Pfizer	USD 15.03B		530M	2026-06
Regeneron Pharmaceuticals	USD 4.29B		690M	2026-06
Vertex Pharmaceuticals	USD 3.33B		340M	2026-06